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The aim of this review is to present in one place a summary of the development of a rabbit 
model of SLE conducted using pedigreed rabbits bred and selected at the National Institute of 
Allergy and Infectious Diseases (NIAID), NIH. We provide an overview of the knowledge 
gained by using rabbits (Oryctolagus cuniculus) as models for SLE, and eliciting autoantibodies 
typical of those produced by patients with SLE. We present here summaries of work by 
ourselves and coauthors that can contribute to improved understanding of neuropsychiatric 
SLE (NPSLE) (Sanches-Guerro et al., 2008). Our gene expression studies (Rai, et al., 2010) and 
extensive evaluations of autoantibody responses coupled with observed clinical symptoms of 
animals immunized against peptides from the Smith antigen (Sm) or the NMDA glutamate 
receptor have shown promise to improve understanding NPSLE. 
An overview of immune system development, genetic diversity of immunoglobulin genes 
and somatic diversification during B-cell development in rabbits can be found in a review 
by Mage et al., (2006) and reference therein. Investigations of autoantibodies found in 
patients with NPSLE and the problems of diagnosis and specific treatments are addressed in 
other chapters in this volume.  
2. Our model  
2.1 Earlier studies of SLE models by other laboratories using rabbit 
We set out to develop a model of SLE in pedigreed rabbits because an earlier report showed 
that immunization of non-pedigreed rabbits with peptides such as PPPGMRPP, derived 
from the Sm B/B’ subunit of the spliceosomal Smith autoantigen led to epitope spreading, 
SLE-like autoantibody production and clinically observed seizures. This peptide sequence is 
one of the major regions of reactivity in SLE patients and may mimic the peptide PPPGRRP 
from the EBNA-1 component of Epstein-Barr virus (EBV) (James et al., 1995). Another study 
attempted to reproduce this report but only found some evidence for epitope spreading 
with no suggestion of induced autoimmunity (Mason et al., 1999). We hypothesized that the 
different results may have been obtained because small numbers of rabbits were studied, 
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and there may have been different genetic susceptibilities among outbred rabbits studied by 
the two groups. Since our work already depended on breeding and maintenance of 
immunoglobulin allotype-defined pedigreed rabbits, we were in a position to pursue this 
idea further.  In addition to using the MAP-8-PPPGMRPP immunogen used in these 
previous studies (termed SM-MAP-8 in the following sections), we chose a new immunogen 
termed GR-MAP-8 based on a report by DeGiorgio et al (2001) that some anti-DNA 
antibodies cross-react with the NMDA glutamate receptor. 
2.2 The model in pedigreed rabbits 
We established a rabbit model of Systemic Lupus Erythematosus (SLE) in which peptide 
immunization led to lupus-like autoantibody production including anti-Sm, -RNP, -SS-A, -
SS-B and -dsDNA. Some neurological symptoms in form of seizures and nystagmus were 
observed (Rai et al., 2006). The animals were selectively bred within the colony of pedigreed, 
immunoglobulin allotype-defined but non-inbred rabbits at the NIAID. We continued 
breeding responders from the first three groups studied (Rai et al., 2006, 2010, Puliyath et al., 
2008, Yang et al., 2009a,b).  Details about genetics, gene expression and cellular studies are 
in the sections below.  The genetic heterogeneity of the pedigreed animals studied may 
correspond to that found among patients of a given ethnicity. 
2.2.1 Methods 
Rabbits: All rabbit experimentation and immunization protocols were reviewed and 
approved by the Animal Care and Use committees of the NIAID, NIH and of Spring Valley 
Laboratories where the animals were bred, housed and monitored. The animals’ 
designations, sexes, and allotypes at the VH a immunoglobulin heavy chain and C b light 
chain loci are summarized in Tables 1A and B. Rabbits of groups 1, 3, 4, 5 and 6 received 
peptides (SM or GR) synthesized on MAP-8 branched lysine backbones and rabbits of group 
2 received the peptides on MAP-4. BB indicates control rabbits that received backbone alone. 
SM animals received MAP-peptide derived from the sequence of the Smith antigen 
spliceosomal B/B' complex. GR animals received MAP-peptide derived from the NMDA 
glutamate receptor sequence. 
Antigens: The peptide immunogens “GR” and “SM” used for the initial rabbit 
immunizations (Rai et al., 2006), were synthesized on branched lysine MAP-8 and MAP-4 
backbones (BB) (AnaSpec) The SM peptide sequence PPPGMRPP corresponds to major 
antigenic regions at 191-198, 216-223 and 231-238 of the nuclear protein Sm B/B’ (James et al, 
1995). The GR peptide sequence DEWDYGLP corresponds to a known rabbit sequence of an 
extracellular epitope of the NR2b subunit of neuronal postsynaptic NMDA receptor.  The 
MAP-BB without peptide was used as a control antigen. For subsequent studies, (Puliyath et 
al., 2008, Yang et al., 2009b, Rai et al. 2010), MAP-8 was the BB of choice because it appeared 
to elicit more diverse autoantibody responses. 
Immunization: Rabbits each received subcutaneous (s.c.) injections of one of the  
MAP-peptides or control BB (0.5 mg/0.5 ml, in borate buffered saline, pH 8.0) emulsified 
with 0.5 ml of complete Freund’s adjuvant (CFA).  Boosts were given s.c. at 3-week 
intervals with the same antigen concentration emulsified with incomplete Freund’s 
adjuvant (IFA). Controls that received only CFA followed by IFA were included in  
one study (Yang et al., 2009b). Sera collected immediately before immunization (pre-
immune) and 1 week after each boost (post-boost) were stored at -20C in multiple 
aliquots for assays. 
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Rabbit ID Rabbit no. Allotype Sex 
Group 1    
SM1 XX129-3 a1/1, b4/5 M 
SM2 2XX127-4 a1/1, b5/5 F 
SM3 2XX288-2 a1/1, b9/9 M 
SM4 1XX288-4 a1/1, b5/9 F 
SM5 2XX127-2 a1/1, b9/9 M 
SM6 2XX92-06 a1/1, b9/9 F 
GR7 XX129-5 a1/1, b4/5 M 
GR8 2XX127-5 a1/1, b9/9 F 
GR9 1XX288-3 a1/1, b5/5 M 
GR10 2XX288-6 a1/1, b5/9 F 
BB11 2XX127-1 a1/1, b5/5 M 
BB12 1XX78-8 a1/1, b9/9 F 
Group 2    
SM13 LL191-1 a1/1, b4/5 M 
SM14 LL191-2 a1/1, b5/5 F 
SM15 2LL179-1 a1/1, b9/9 M 
SM16 1LL163-3 a1/1, b9/9 F 
SM17 LL164-4 a1/1, b9/9 F 
GR18 1LL178-2 a1/1, b9/9 M 
GR19 1LL178-3 a1/1, b4/4 F 
GR20 1LL178-4 a1/1, b9/9 F 
GR21 1LL178-5 a1/1, b4/9 M 
GR22 1LL178-6 a1/1, b4/9 F 
GR23 1LL178-8 a1/1, b4/4 F 
BB24 LL164-1 a1/1, b9/9 M 
BB25 LL164-3 a1/1, b9/9 F 
BB26 2LL179-3 a1/1, b5/9 M 
BB27 1LL163-4 a1/1, b5/9 F 
Group 3    
GR28 LL108-1 a1/1, b5/9 M 
GR29 LL108-3 a1/1, b5/5 F 
GR30 LL108-4 a1/1, b9/9 F 
BB31 2LL179-2 a1/1, b9/9 M 
Group 4    
SM32 1QQ299-2 a1/1, b5/5 M 
SM33 1QQ299-3 a1/1, b4/5 F 
SM34 6QQ299-1 a1/1, b4/9 M 
SM35 6QQ299-2 a1/1, b4/5 F 
GR36 3QQ299-1 a1/1, b4/5 M 
GR37 3QQ299-2 a1/1, b5/9 M 
GR38 3QQ299-4 a1/1, b5/9 M 
GR39 4QQ299-1 a1/1, b5/9 M 
GR40 5QQ299-2 a1/1, b5/9 F 
GR41 5QQ299-3 a1/1, b5/5 F 
BB42 1QQ299-1 a1/1, b5/5 M 
BB43 5QQ299-4 a1/1, b5/5 F 
BB44 6QQ299-3 a1/1, b4/9 F 
PB45 1QQ173-1 a1/1, b5/9 M 
PB46 1QQ173-2 a1/1, b5/5 M 
PB47 1QQ173-3 a1/1, b5/5 M 
Table 1. A. Designations of sexes and allotypes of Groups 1-4. 
PB45, 46, and 47 received injections with phosphate buffered saline only. 
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Group 5    
GR 48 UA345-1 a2/2, b9k/9k M 
GR49 1UA344-1 a1/2, b9k/9k M 
GR50 1UA344-5 a1/2, b9k/9k F 
GR51 1YY119-6 a1/1, b9/9 F 
GR52 1YY119-8 a1/1, b9/9 F 
GR53 2YY119-6 a1/1, b9/9 M 
GR54 2YY299-5 a1/1, b4/9 F 
GR55 2YY299-3 a1/1, b4/9 F 
GR56 UA345-2 a1/2, b4/9k M 
GR57 1UA344-2 a1/2, b5/9k M 
GR58 1UA344-6 a2/2, b5/9k F 
GR59 1YY119-7 a1/1, b9/9 F 
GR60 1YY327-2 a1/1, b5/9 M 
GR61 2YY327-9 a1/1, b4/5 F 
GR62 2YY299-4 a1/1, b4/9 F 
GR63 2YY119-8 a1/1, b9/9 F 
BB64 UA345-4 a2/2, b9k/9k F 
BB65 2UA344-1 a1/2, b9k/9k F 
BB66 1UA344-3 a2/2, b5/9k M 
BB67 2YY327-8 a1/1, b4/5 M 
BB68 UA345-6 a1/2, b4/9k F 
BB69 1YY327-4 a1/1, b5/9 F 
BB70 1YY119-5 a1/1, b9/9 M 
BB71 2YY119-7 a1/1, b9/9 M 
Group 6    
GR72 UA345-5 a2R3/2R3, 4/9k F 
GR73 UA269-3 a1/1, b4/9k F 
BB74 6YY328-4 a1/1, b5/9 M 
BB75 2YY125-6 a1/2, b9k/9k M 
CF1 6YY328-3 a1/1, b5/9 M 
CF2 1UA161-1 a1/1, b9/9 M 
GR76 2YY119-9 a1/1, b9/9 F 
GR77 UA269-1 a1/1, b4/5 M 
BB78 YY118-6 a1/1, b9/9 M 
BB79 1UA161-2 a1/1, b9/9 M 
CF3 1YY125-4 a2/2, b4/9k M 
CF4 2YY125-4 a2/2, b5/9k M 
GR80 XA345-1 a1/2, b9/9k F 
GR81 2UA14-2 a1/1, b5/9 F 
BB82 XA346-2 a1/1, b9/9 M 
BB83 2UA14-3 a1/1, b5/9k F 
CF5 XA345-2 a1/2, b9/9k F 
GR84 XA234-2 a1/2, b5/9 F 
GR85 XA346=1 a1/1, b9/9 M 
BB86 XA234-2 a1/2, b5/9 M 
B87 3XA203-2 a1/ali M 
CF6 2XA344-2 a1/1, b9/9 F 
CF7 1XA344-1 a1/1, b9/9 M 
Table 1. B. Designations of sexes and allotypes of Groups 5 and 6. 
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Clinical Assessments: Rabbits were housed in a separate room equipped with video 
surveillance so that abnormal behavior such as seizure activity and other neurological 
dysfunctions could be detected.  They were observed daily and also received periodic 
complete health evaluations. Hematology using a Bayer Advida, model 120 hematology 
analyzer and blood chemistry assessments of each rabbit were carried out in a Veterinary 
diagnostic laboratory (Antech Diagnostics, Lake Success NY).  
ELISA for anti-peptide antibodies, anti-dsDNA and autoantibodies to nuclear antigens: 
Serum antibody responses to the MAP-peptides and control immunogens were measured 
by solid phase ELISA as previously described (Rai et al 2006). “Polystyrene 96-well plates 
(Corning Inc, Corning, NY, Cat # 3590) were coated with 50 l/well of either SM-, GR- or 
BB- (MAP-8 or MAP–4) at 10 g/ml in bicarbonate buffer, (pH 9.6) and incubated overnight 
at 40C.  Plates were washed three times with PBS (pH 7.2) containing 0.1% Tween 20 and 
blocked with 100 l blocking solution for 1 hr at 370C (Quality Biological Inc, Gaithersburg, 
MD).  Wells were then incubated 1 hr, at 370C with 50 l/well of sera titrated by four-fold 
dilutions in blocking solution, washed 5 times, incubated for 1 hr at 370C with 50 l of a 
1:2000 dilution (0.4 ng/l) of affinity-purified horseradish peroxidase conjugated (HRP) 
goat anti-rabbit IgG (H+L) secondary antibody (Jackson Immunoresearch Laboratories Inc., 
West Grove, PA), developed with 3, 3', 5, 5'- tetramethylbenzidine (TMB) (Inova 
Diagnostics, Inc., San Diego, CA) and the resulting OD read at 450 nm.”  
Commercially available human diagnostic kits (INOVA Diagnostics) were adapted and 
used to assay serum autoantibodies to total extractable nuclear Ags (ENA) and to 
component Ags Sm, Rnp, SS-A, SS-B. Assays for autoantibodies to calf thymus dsDNA were 
adapted similarly using two different commercially available kits (Vidia, Vestec (Kit A); 
Zeus scientific, NJ (Kit B).  Briefly, 100 l rabbit sera diluted 1:100 in the proprietary sample 
diluents were added to antigen-coated wells and incubated for 60 min. at 37C (Kit A) or 30 
min. at RT (Kit B).  Wells were then washed, incubated for 60 min. at 37C (Kit A) or 30 min 
at RT (Kit B) with secondary antibody HRP-goat anti-rabbit IgG Fc (Jackson 
Immunoresearch Laboratories, Inc.) and developed with TMB for reading OD at 450 nm. For 
groups 5 and 6, anti-dsDNA, -ANA, -RNP and -Sm were assayed with the Quantalite kits 
(Inova Diagnostics) substituting affinity purified HRP-goat anti-rabbit IgG Fc for the anti-
human secondary reagent (Puliyath et al., 2008, Yang et al., 2009b). 
Detection of anti-nuclear antibodies (ANA) by indirect immunofluorescence: 
Commercially available slides coated with fixed Hep-2 cells (Antibodies Inc., Davis, CA) 
were incubated with rabbit antisera diluted 1:20 in 5% goat serum (Jackson Immunoresearch 
Laboratories Inc.) for 30 min. at RT.  ANA binding was detected by fluorescence microscopy 
following 30 min incubation at RT with 12.5 ng/l of FITC-goat anti-rabbit IgG Fc (Southern 
Biotech Inc., Birmingham, AL).  Fluorescent binding patterns were compared with reference 
pictures provided by Antibodies, Inc.  
Flow cytometry: Anti-human antibodies that cross reacted with rabbit B-cell activation 
factor (BAFF) (biotin conjugated goat anti-human BAFF polyclonal antibody), 
transmembrane activator and CAML interactor (TACI) (biotin conjugated goat anti-human 
TACI polyclonal antibody)(Antigenix, America, Inc.), BAFF receptor (BR3) (purified goat 
anti-human BR3 antibody) (R&D systems) were used for staining. Briefly, purified PBMCs 
were incubated on ice for 40 min with primary antibody before washing twice with cold PBS 
containing 1% FCS, then subsequent incubation with various secondary reagents or 
secondary antibodies. For BR3 detection, a biotinylated donkey anti-goat IgG was used as 
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secondary antibody. Biotinylated antibodies were visualized by PE-conjugated streptavidin 
(Jackson ImmunoResearch laboratories, Inc.). After washing, cells were analyzed using a 
FACS-Calibur flow cytometer  (BD Pharmingen) and FlowJo analytical software (Tree Star). 
Cells were gated on the side scatter x forward scatter (SSCxFSC) profiles to include both 
small and large lymphocytes, as well as monocytes but exclude red blood cells and 
granulocytes; dead cells were excluded by propidium iodide staining. Rabbit IgM+ B cells 
were detected by FITC-conjugated goat anti-rabbit IgM (Southern Biotechnology 
Associates). 
Gene Expression studies: RNA extraction and synthesis of cDNA and cRNA 
Peripheral white blood cells (PWBCs) were lysed with TRIzol (Invitrogen, CA) and total 
RNA was extracted using RNAeasy Mini columns following the manufacturer’s instructions 
(Qiagen, CA). The cRNA probes were prepared from mRNA using the Affymetrix gene chip 
eukaryotic small sample target labeling protocol assay version II (Affymetrix, Santa Clara, 
CA) using 2 cycles of cDNA synthesis and in vitro transcription (IVT) reactions. The cRNA 
thus obtained was used in the final IVT cycle for obtaining biotinylated cRNA using CTP 
and UTP (EnzoBioarray, Enzo Life Sciences, Farmingdale, NY) (Rai et al 2010).   
Microarray analysis Affymetrix U95A human microarray chips were used and hybridization 
of the labeled cRNA was carried out according to the manufacturer's recommended 
protocol.  Non-normalized MAS5 signals were used to compare raw probeset intensity 
values between human and rabbit samples. Final rabbit study analyses were conducted with 
expression values summarized using dChip, log2 transformed and Loess normalized using 
an R package (http://www.elwood9.net/spike). Analyses of the gene sets were done using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/knowledgebase/) and Ingenuity Pathways Analysis (IPA) 
(Ingenuity Systems, Mountain View, CA; www.ingenuity.com). 
Quantitative real time PCR: Quantitative real time PCR analysis of mRNAs was performed 
on a 7900HT Sequence Detection System (Applied Biosystems). The cDNA synthesized from 
isolated PWBCs was directly used as template for real-time PCR by using TaqMan 2x PCR 
Master Mix Reagents Kit (Applied Biosystems). Each sample from three independent 
experiments was run in duplicate.  The unit number showing relative mRNA levels in each 
sample was determined as a value of mRNA normalized against Peptidylprolyl isomerase A 
(PPIA). RT-PCR data were analyzed by using the 2−CT method. Based on its uniform 
expression among rabbit groups in the microarray analysis, rabbit peptidylprolyl isomerase 
A (PPIA; cyclophilin A) was selected as the housekeeping gene control and used for the 
calculation of CT. Where rabbit sequences were unavailable, primers were designed after 
searching for rabbit sequences with corresponding human gene sequences in the database 
containing the trace archives of the whole genome shotgun sequence of the rabbit 
(Oryctolagus cuniculus) generated by the Broad Institute of MIT and Harvard University 
(NCBI trace archive: cross- species Megablast at http://www.ncbi.nlm.nih.gov/blast/ 
tracemb.shtml) and in assemblies of rabbit scaffolds at Ensembl and UCSC (see NCBI Rabbit 
Genome Resources site) at: http://www.ncbi.nlm.nih.gov/projects/genome/guide/rabbit/ 
2.2.2 Genetics and autoantibody responses 
Figure 1 shows the pedigree and an overview of antibody responses of the rabbits 
immunized and selectively bred during the project to develop a rabbit model of SLE. There 
were 31 1- to 2-year-old rabbits in the initial studies (Rai et al., 2006). Rabbits of groups 2 or 
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3 were descendants of rabbits of groups 1 or 2 and/or their siblings. Rabbits that did not 
respond with autoantibody production after immunization during this initial study by Rai 
et al., (2006) are not shown. The fourth group was described in Rai et al., (2010) and their 
mRNA included along with mRNA from the first three groups for gene expression profiling 
of a total of 46 pedigreed control- or immunized-rabbits as detailed below (section 2.2.3). 
Controls that received only phosphate buffered saline are designated PB. Because the  
GR peptide generally elicited better autoantibody responses than the SM peptide, the  
two subsequent groups [5 (Puliyath et al., 2008) and 6 (Yang et al., 2009b)] were immunized 
with GR-MAP-8 or control BB-MAP-8. The final 6th group also included controls that 
received complete followed by incomplete Freund’s adjuvant but no MAP-BB or  
MAP-peptide, to investigate whether adjuvants alone led to any autoantibody production 
(designated CF).  
An overview of autoantibody responses, and the relationships of males (squares) and 
females (circles) in six immunization groups is shown in Figure 1. The four quadrants 
indicate post-immunization elevations of levels of anti-dsDNA (upper left), anti-Sm and/or 
anti-RNP (lower left), ANA by IFA (upper right) and ANA by ELISA (lower right). For the 
5th (Puliyath et al. 2008) and 6th groups (Yang et al., 2009b), darker shades indicate high 
autoantibody responses. The large circles and squares represent the 6th group developed 
from selective breeding using responders from earlier groups. Figure originally published 
by Yang et al., (2009b) Investigations of a rabbit (Oryctolagus cuniculus) model of systemic 
lupus erythematosus (SLE), BAFF and its receptors. PLoS ONE Vol. 4, 2009. 
The selective breeding led to subsequent progeny (groups 5 and 6) exhibiting more 
consistent autoantibody production. In the pedigree, we can trace the ancestry of some 
responder rabbits back to the first high responders (SM1 and GR9) that also exhibited 
seizures. For example, GR54 and GR55 from litter 2YY299 had high-responder grandsires 
SM1 and SM15 (Puliyath et al. 2008). The model developed using selectively bred pedigreed 
rabbits remains a promising one for further genetic investigations. 
As is found in human sera (Li et al., 2011), some rabbits had detectable pre-immune anti-
nuclear antibodies (ANA) by ELISA. ANA of sixteen of twenty-four rabbits in group 5, 
including four immunized with only MAP-8 backbone had an increased ELISA value (delta 
OD) above pre-immune of 1.0 or more optical density units after the third boost. Anti-
dsDNA increased in 12/24 rabbits after the fifth or seventh boost (Puliyath et al., 2008). 
Figure 2 shows examples of indirect immunofluorescence (ANA-IFA) studies of some sera 
from group 6 (Yang et al. 2009b). As in human SLE sera, the ANA-IFA patterns reflect 
responses to one or more autoantigens in different individuals. Littermates that received GR 
peptide such as UA269-3 and -1 (GR73 and GR77) developed similar patterns after the 3rd 
boost. ANA staining with sera of littermates XA346-1 and -2 (GR85 and BB82) resulted in 
different patterns. GR85 serum exhibited some cytoplasmic and peripheral nuclear staining 
not seen with the serum of BB82.  Puliyath et al., (2008) also noticed that GR-immunized 
littermates had similar ANA-IFA staining patterns but that BB immunized animals’ patterns 
generally differed. 
2.2.3 Gene expression studies 
We extended the information about the rabbit model of SLE by microarray-based  
expression profiling of mRNA from peripheral blood leukocytes following peptide 
immunization (Rai et al., 2010). Data obtained in studies of gene expression in the first four 
groups of immunized rabbits were deposited in the Gene Expression Omnibus and became  
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Fig. 1. Pedigree and summary of autoantibody responses. 
www.intechopen.com
 A Rabbit Model of Systemic Lupus Erythematosus, Useful for Studies of Neuropsychiatric SLE 
 
209 
public on Jul 23, 2010 at the NCBI website: http://www.ncbi.nlm.nih.gov/geo/query/ 
acc.cgi?acc=GSE23076  
Experiment type: Expression profiling by array. GEO accession: Series GSE23076 Query 
DataSets for GSE23076 
 
 
Fig. 2. Examples of indirect ANA-IFA assays of pre- and post-immune sera. Figure 
originally published by Yang et al., (2009b) Investigations of a rabbit (Oryctolagus cuniculus) 
model of systemic lupus erythematosus (SLE), BAFF and its receptors. PLoS ONE  
Vol.4, 2009. 
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At the time of the gene expression studies, microarrays specific for study of gene expression 
profiles were not available for rabbits. We therefore first conducted comparisons of 
identically prepared rabbit and human cRNA binding to the Affymetrix U95 microarray 
available for human gene expression analyses. We showed that the human microarray could 
be used with rabbit cRNA to yield information on genetic pathways activated and/or 
suppressed in autoantibody-producing immunized rabbits. After demonstrating that human 
expression arrays could be used with rabbit RNA to yield information on molecular 
pathways, we designed a study evaluating gene expression profiles in a total of 46 rabbits 
from 4 groups of the pedigreed control and immunized rabbits. We discovered unique gene 
expression changes associated with lupus-like serological patterns in immunized rabbits. 
Our results also demonstrated that caution must be applied when choosing the structure of 
the carrier Multiple Antigen Peptide (MAP-peptide) for immunization. We discovered that 




Fig. 3. Gene expression patterns differ when the backbone of immunogen is MAP-4 (A) or 
MAP-8 (B). In panel A, Cluster 1 genes were overrepresented in the SM group, Cluster 2 
were common to both, Cluster 3 genes were overexpressed in the GR group and Cluster 4 
genes were decreased in expression in both groups. Count indicates the number of different 
genes associated with each functional term. Figure modified from one originally published 
in The Journal of Immunology. Rai, G., Ray S., Milton, J., Yang, J., Ren, P., Lempicki, R., and 
Mage, R.G. 2010. Gene expression profiles in a rabbit model of systemic lupus 
erythematosus autoantibody production. J. Immunol. 185:4446-4456. Copyright © [2010] The 
American Association of Immunologists, Inc.  
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Figure 3 shows that distinct patterns and clusters of functionally related genes were found 
to be upregulated when peptides SM or GR on MAP-4 backbone (A) were used as 
immunogens compared to when MAP-8 backbone was used (B) (Rai et al., 2010). Validation 
of gene expression data by quantitative real-time PCR was conducted for two genes for 
which primer sequences were available beta2-microglobulin (B2M) and p-21-protein 
(Cdc42/Rac)-activated kinase 1 (PAK1) (Figure 6 in Rai et al., 2010).  These genes appear in 
the interactive pathway shown in Figure 4 below. Among the genes significantly 
upregulated in SLE rabbits were those associated with NK cytotoxicity, antigen 
presentation, leukocyte migration, cytokine activity, protein kinases, RNA spliceosomal 
ribonucleoproteins, intracellular signaling cascades, and glutamate receptor activity (Rai et 
al., 2010). 
 
Functional Annotation p-Value Number of molecules 
Inflammatory Disorder 1.6E-11 25 
Immunological Disorder 3.1E-11 23 
Rheumatic Disease 5.4E-11 19 
Autoimmune Disease 2.7 E-08 18 
Rheumatoid Arthritis 1.7E-06 13 
Glomerulonephritis 2.6E-06 5 
Inflammation 2.5E-05 7 
Lupus Nephritis of Mice 3.2E-04 3 
Table 2. The top functional annotations found using Ingenuity Pathways Analysis (IPA) in 
comparisons of upregulated genes of rabbits making anti-dsDNA to those only making 
other anti-nuclear antibodies. 
Figure 4 and Table 2 summarize the patterns of upregulated gene expression found in the 
rabbits from the three groups immunized with MAP-8-peptides that made anti-dsDNA 
compared to those that only made other anti-nuclear antibodies. Twenty-five genes 
associated with inflammatory disorders were significantly upregulated in expression.  
Subsets of these were associated with various immunological disorders in the IPA databases 
including Autoimmune, Rheumatic, and inflammatory diseases. The results linked 
increased immune activation with up-regulation of components associated with 
neurological and anti-RNP responses, demonstrating the utility of the rabbit SLE model to 
uncover biological pathways related to SLE-induced clinical symptoms, including NPSLE. 
We suggested that our finding of distinct gene expression patterns in rabbits that made anti-
dsDNA should be further investigated in subsets of SLE patients with different 
autoantibody profiles (Rai et al., 2010). In Figure 4, the connecting lines indicate direct 
interactions among the products of these genes. The shapes classify the proteins found as 
transmembrane receptors e.g. CD 40, cytokines/growth factors, e.g. CCL2, kinases, e.g. TYK2, 
peptidases, e.g. MMP9, other enzymes, e.g. ARF1 and transcriptional regulators, e.g. STAT5B. 
Genes shown were common to the pathways listed in Table 2 that were upregulated in the 
anti-dsDNA positive rabbits. Figure 4 was modified from one originally published in the 
Journal of Immunology. Rai, G., Ray S., Milton, J., Yang, J., Ren, P., Lempicki, R., and Mage, 
R.G. 2010. Gene expression profiles in a rabbit model of systemic lupus erythematosus 
autoantibody production. J. Immunol. 185:4446-4456. Copyright © [2010] The American 
Association of Immunologists, Inc.  
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Fig. 4. Interactive pathway network of upregulated genes in anti-dsDNA positive rabbits.  
2.2.4 Rabbit BAFF 
Our laboratory described the expression and localization of rabbit B-cell activating factor 
(BAFF also termed BLys, TNFSF13b TALL1, zTNF4) and its receptor BR3 in cells and tissues of 
the rabbit (Yang et al., 2009a). In addition to its important role in B-cell development and 
survival, disease activity in human lupus patients has been reported to correlate with serum 
BAFF levels (reviewed in Groom et al., 2007) and with elevated expression of mRNA for BAFF 
and two BAFF receptors, BR3 and transmembrane activator and CAML interactor (TACI) in 
PBMC of lupus patients (Petri et al, 2008).  We therefore also investigated BAFF and its 
receptors in our rabbit model of SLE (Yang et al., 2009b). We previously concluded that BAFF 
detected on B cells by flow cytometry represented BAFF bound to its receptors on the cells 
(Yang et al, 2009a). An independent study (Yeramilli, & Knight, 2010) also reported that BAFF-
binding receptors on rabbit B-cells are occupied by endogenous soluble BAFF. These authors’ 
studies also suggested that B cells in rabbit could produce BAFF. With the small number of 
total animals available in group 6 (Table 1B), and no reagents available to detect levels of 
serum BAFF, we could only measure BAFF on cell surfaces by flow cytometry. These studies 
found decreased surface expression of BAFF, BR3 and TACI after immunization and boosting 
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in most animals.  However, two rabbits that produced high anti-dsDNA responses (GR76 and 
GR77) developed higher percentages of BAFF/CD14 and BR3/CD14 positive cells. We did 
observe consistently lower mean fluorescence intensities of staining of TACI on PBMC and 
lower percentages of TACI positive cells. We suggested that since TACI is a negative regulator 
of B cells in mouse and man, perhaps the decrease in TACI in the rabbits producing 
autoantibodies had allowed autoreactive B cells to escape regulation. 
At the time these studies were conducted, clinical trials targeting BAFF/BLys and its 
receptors were in progress. With the FDA approval of Benlysta® (belimumab) in March, 
2011, this monoclonal antibody, that inhibits binding of BLys/BAFF to receptors on B cells, 
became the first United States FDA approved treatment for SLE in over fifty years. 
Unfortunately, the clinical trials did not include SLE patients with severe active central 
nervous system lupus or nephritis. Post-approval trials will be required before this 
treatment can be recommended for these cohorts of patients. 
2.3 Future prospects 
2.3.1 Detection of autoantibodies to other antigens including neuroantigens in the 
rabbit model 
In our rabbits, the development of severe symptoms may not yet have occurred because 
many were euthanized to make room for immunization and testing of their progeny and for 
tissue collection. For example, although nephritis was not observed, our gene expression 
studies identified upregulation of genes associated with Glomerulonephritis and also found 
in mice with Lupus Nephritis (Table 2 and Figure 4). Protein arrays containing microbial 
and autoantigens have been used to extend information on patients’ serum profiles beyond 
the standard tests used in diagnosis (see for example, Robinson et al., 2002; Quintana et al., 
2004; Li et al., 2005; Fattal et al. 2010). Recently, Li et al, (2011) used protein microarrays to 
determine risk factors for ANA positivity in healthy persons and concluded that serum 
profiles of autoantibodies can potentially identify healthy individuals with potential to 
develop lupus and other autoimmune diseases. Their observations extended the widely 
quoted earlier observations by Arbuckle et al, (2003) that autoantibodies develop as much as 
ten years before the clinical onset of SLE. In a NOD mouse model of cyclophosphamide-
accelerated diabetes, Quintana et al (2004) used a protein microarray to predict from 
autoantibody repertoires, resistance or susceptibility to the development of diabetes before 
the induction with cyclophosphamide. Recently Fattal et al, (2010) applied the same 
technology to studies of SLE patients and controls.  They reported highly specific SLE 
profiles that typically show increases in IgG binding to dsDNA, single-stranded DNA, 
Epstein–Barr virus, and hyaluronic acid. Interestingly, a healthy control subject who had the 
SLE antibody profile was later found to develop clinical SLE. Decreases in some specific IgM 
reactivities to autoantigens observed in this and earlier studies (Li et al., 2005) suggest that 
some natural IgM autoantibodies may play a protective role. A project to determine the 
antibody profiles of the rabbits’ serum IgG and IgM, purified anti-dsDNA, and anti-peptide 
on protein microarrays carrying microbial and self antigens including those from the central 
and peripheral nervous system is in progress. 
2.3.2 NPSLE and anti-NMDA glutamate receptors  
The suggestion from extensive studies in the laboratory of Betty Diamond that some anti-
dsDNA antibodies may react with the NMDA receptor and contribute to neurological 
manifestations in some lupus patients (DeGiorgio et al. 2001; Kowal et al, 2004), has led to 
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numerous follow-up studies by the Diamond group, (Diamond & Volpe, 2004) and others. A 
recent editorial (Appenzeller, 2011) provides an updated overview of controversies in the 
field and discusses the accompanying paper by Gono et al., (2011) who report new analyses 
of 107 patients’ sera for cross-reactivities of anti-dsDNA with a peptide derived from the 
sequence of the human NMDA receptor 2A (NR2A) compared with the similar peptide from 
human NR2B. They suggest that the sensitivity for detection of autoantibodies is greater 
with the NR2A peptide although their ELISA results directly comparing serum reactivities 
with each peptide were correlated with high significance (r = 0.94; P<0.0001). They conclude 
that assays of sera for anti-NR2A antibodies may be a better predictor of NPSLE than assays 
for NR2B and suggest that mixed results from other similar studies may be explained by 
small numbers of patients (Husebye et al., 2005) or less sensitive assays. We chose the GR 
peptide used in our immunization protocol based on the human sequence of NR2B because 
the rabbit sequence was not yet known. However, we knew that this sequence was highly 
conserved in several species including mouse, rat, dog, cow and chicken.  
2.3.3 Rabbit genomics 
Future studies of rabbit autoimmune and infectious diseases will benefit from the 
availability of a high quality draft rabbit genome sequence and assembly at ~7 x coverage 
recently completed at the Broad Institute, Boston (OryCun2.0). The donor was from a 
partially inbred strain. NCBI maintains a Rabbit Genome Resources website: 
http://www.ncbi.nlm.nih.gov/projects/genome/guide/rabbit/ 
Rabbit genomic sequences and assemblies from the ENCODE Project, with ~ 1% of rabbit 
genomic sequence from a different, outbred NZW animal are also available in GenBank. The 
selection of peptides for future immunization studies in rabbits can benefit from searching 
these resources. 
3. Conclusion 
The work described in this review documents that rabbits have a strong genetic component 
that leads to predisposition to production of autoantibodies similar to those found in SLE 
patients including those with NPSLE. Breeding and selection for consistent autoantibody 
production in the rabbit model can be accomplished over a few generations.  When one of 
us (RGM) retired to Emeritus status at NIAID, the pedigreed colony was no longer 
maintained.  Some animals related to those studied were distributed to others. In addition, 
although the pedigreed colony was dispersed, there is sperm available from two male 
breeders rabbits LL191-1 (SM13) and 1UA344-1 (GR49). In particular male SM13 and his 
progeny in the breeding scheme shown in Figure 2 generated numerous responders that 
made autoantibodies similar to those found in human Lupus patients. Cryovials of sperm 
from these animals are currently stored at the Twinbrook 3 facility of the Comparative 
Medicine Branch (CMB) of NIAID in liquid nitrogen storage tanks, and monitored weekly 
by their personnel.  Further contact information can be obtained at the website of the CMB, 
of the NIAID, NIH at: http://www.niaid.nih.gov/LabsAndResources/labs/aboutlabs/ 
cmb/Pages/default.aspx.  
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